Nasus Pharma Ltd. (NSRX)
NSRX trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/2029039/000149315226012559/0001493152-26-012559-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | NSRX on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Not reported by the screener |
| IPO year | 2025 |
| SEC CIK | 0002029039 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Israel |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.2B |
| Net income | -$5.9M |
| Operating income | -$4.9M |
| Net margin | -0.5% |
| Operating margin | -0.4% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $1.2M |
| Total assets | $5.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "This has led management to conclude that there is substantial doubt about our ability to continue as a going concern." | 20-F 2026-03-25 |
| Cash and burn | $1.2M cash; operating cash flow -$1.2M a quarter. | Report 2025-12-31 |
| Shares outstanding | 9,015,383 (2025-12-31). the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-09-18 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Brightman Almagor Zohar & Co., Tel Aviv, Israel | PCAOB Form AP 2026-04-28 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $62K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $1.2B | -$5.9M | -$4.9M | $1.2M | No debt tags | $1.2B | 20-F 2026-03-25 |
| FY 2024 2024-12-31 | Not filed | -$1.5M | -$665K | $284K | $1.8M | Needs four quarters | 20-F 2026-03-25 |
| FY 2023 2023-12-31 | Not filed | -$1.1M | -$1.0M | $193K | No debt tags | Needs four quarters | 20-F 2026-03-25 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-09-18 |
| Latest annual report | 20-F | 2026-03-25 |
| Latest quarterly / interim | 6-K | 2026-11-16 |
Source: SEC EDGAR submissions feed, 104 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +1.8% |
| 1 month | -9.2% |
| 3 months | -10.3% |
| Year to date | -68.6% |
| 1 year | -63.7% |
| From 52-week high | -68.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NNVC | NanoViricides Inc. | $1.24 | +0.81% | $31.7M |
| NXTC | NextCure Inc. | $6.68 | +4.38% | $30.6M |
| PMN | ProMIS Neurosciences Inc. Common Shares (ON) | $3.31 | +0.61% | $29.8M |
| SCYX | SCYNEXIS Inc. | $2.91 | -9.35% | $29.0M |
| BCTX | BriaCell Therapeutics Corp. Common Shares | $3.30 | -2.65% | $28.8M |
| RNTX | Rein Therapeutics Inc. | $0.4000 | -27.55% | $34.5M |
| AARD | Aardvark Therapeutics Inc. | $1.26 | -5.26% | $27.6M |
| OSTX | OS Therapies Incorporated | $0.6807 | -8.63% | $35.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier